{
  "guideline": {
    "id": "PA166176068",
    "name": "Annotation of CPIC Guideline for tamoxifen and CYP2D6",
    "source": "CPIC",
    "version": 12,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166176068",
    "relatedChemicals": [
      {
        "id": "PA451581",
        "name": "tamoxifen",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166298391",
      "name": "Recommendation PA166298391",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060993,
        "html": "<p>Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).</p>\n"
      },
      "implications": [
        "CYP2D6: Therapeutic endoxifen concentrations"
      ],
      "lookupKey": {
        "CYP2D6": "3.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298237",
      "name": "Recommendation PA166298237",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060839,
        "html": "<p>Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).</p>\n"
      },
      "implications": [
        "CYP2D6: Therapeutic endoxifen concentrations"
      ],
      "lookupKey": {
        "CYP2D6": "4.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298527",
      "name": "Recommendation PA166298527",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061129,
        "html": "<p>Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.</p>\n"
      },
      "implications": [
        "CYP2D6: Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers."
      ],
      "lookupKey": {
        "CYP2D6": "0.75"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298523",
      "name": "Recommendation PA166298523",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061125,
        "html": "<p>Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).</p>\n"
      },
      "implications": [
        "CYP2D6: Therapeutic endoxifen concentrations"
      ],
      "lookupKey": {
        "CYP2D6": "1.75"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166301328",
      "name": "Recommendation Annotation PA166301328",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452095647,
        "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x≥3</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x≥3</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x≥3</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x≥3</strong> or <strong>*2x2 versus *2x≥3</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x≥3</td>\n<td>Increased</td>\n<td>≥3</td>\n<td></td>\n<td></td>\n<td>≥3</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "xN combinations"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298520",
      "name": "Recommendation PA166298520",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061122,
        "html": "<p>Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).</p>\n"
      },
      "implications": [
        "CYP2D6: Therapeutic endoxifen concentrations"
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298507",
      "name": "Recommendation PA166298507",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061109,
        "html": "<p>Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).</p>\n"
      },
      "implications": [
        "CYP2D6: Therapeutic endoxifen concentrations"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298528",
      "name": "Recommendation PA166298528",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061130,
        "html": "<p>Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.</p>\n"
      },
      "implications": [
        "CYP2D6: Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers."
      ],
      "lookupKey": {
        "CYP2D6": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298524",
      "name": "Recommendation PA166298524",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061126,
        "html": "<p>Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).</p>\n"
      },
      "implications": [
        "CYP2D6: Therapeutic endoxifen concentrations"
      ],
      "lookupKey": {
        "CYP2D6": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298380",
      "name": "Recommendation PA166298380",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060982,
        "html": "<p>Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).</p>\n"
      },
      "implications": [
        "CYP2D6: Therapeutic endoxifen concentrations"
      ],
      "lookupKey": {
        "CYP2D6": "2.75"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298530",
      "name": "Recommendation PA166298530",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061132,
        "html": "<p>Recommend alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827) and based on knowledge that CYP2D6 poor metabolizers switched from tamoxifen to anastrozole do not have an increased risk of recurrence (PMID 23213055). Note, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy (PMID 27226358, 21768473).</p>\n"
      },
      "implications": [
        "CYP2D6: Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers."
      ],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297837",
      "name": "Recommendation PA166297837",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060439,
        "html": "<p>Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).</p>\n"
      },
      "implications": [
        "CYP2D6: Therapeutic endoxifen concentrations"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298464",
      "name": "Recommendation PA166298464",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061066,
        "html": "<p>Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).</p>\n"
      },
      "implications": [
        "CYP2D6: Therapeutic endoxifen concentrations"
      ],
      "lookupKey": {
        "CYP2D6": "2.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298508",
      "name": "Recommendation PA166298508",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061110,
        "html": "<p>Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).</p>\n"
      },
      "implications": [
        "CYP2D6: Therapeutic endoxifen concentrations"
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298531",
      "name": "Recommendation PA166298531",
      "population": "general",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061133,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "n/a"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297353",
      "name": "Recommendation PA166297353",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452059955,
        "html": "<p>Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).</p>\n"
      },
      "implications": [
        "CYP2D6: Therapeutic endoxifen concentrations"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298529",
      "name": "Recommendation PA166298529",
      "population": "general",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061131,
        "html": "<p>Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.</p>\n"
      },
      "implications": [
        "CYP2D6: Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers."
      ],
      "lookupKey": {
        "CYP2D6": "0.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298521",
      "name": "Recommendation PA166298521",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061123,
        "html": "<p>Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).</p>\n"
      },
      "implications": [
        "CYP2D6: Therapeutic endoxifen concentrations"
      ],
      "lookupKey": {
        "CYP2D6": "2.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298155",
      "name": "Recommendation PA166298155",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060757,
        "html": "<p>Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).</p>\n"
      },
      "implications": [
        "CYP2D6: Therapeutic endoxifen concentrations"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298525",
      "name": "Recommendation PA166298525",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061127,
        "html": "<p>Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).</p>\n"
      },
      "implications": [
        "CYP2D6: Therapeutic endoxifen concentrations"
      ],
      "lookupKey": {
        "CYP2D6": "1.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298526",
      "name": "Recommendation PA166298526",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061128,
        "html": "<p>Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.</p>\n"
      },
      "implications": [
        "CYP2D6: Lower endoxifen concentrations compared to normal metabolizers; higher risk of breast cancer recurrence, event-free and recurrence-free survival compared to normal metabolizers."
      ],
      "lookupKey": {
        "CYP2D6": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298522",
      "name": "Recommendation PA166298522",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061124,
        "html": "<p>Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).</p>\n"
      },
      "implications": [
        "CYP2D6: Therapeutic endoxifen concentrations"
      ],
      "lookupKey": {
        "CYP2D6": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166298482",
      "name": "Recommendation PA166298482",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061084,
        "html": "<p>Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).</p>\n"
      },
      "implications": [
        "CYP2D6: Therapeutic endoxifen concentrations"
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [
    {
      "pmid": "29385237",
      "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.",
      "authors": [
        "Goetz Matthew P",
        "Sangkuhl Katrin",
        "Guchelaar Henk-Jan",
        "Schwab Matthias",
        "Province Michael",
        "Whirl-Carrillo Michelle",
        "Symmans W Fraser",
        "McLeod Howard L",
        "Ratain Mark J",
        "Zembutsu Hitoshi",
        "Gaedigk Andrea",
        "van Schaik Ron H",
        "Ingle James N",
        "Caudle Kelly E",
        "Klein Teri E"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2018
    }
  ],
  "version": "2024-03-25-16-13"
}